Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Sarcoma, Alveolar Soft Part 1Recurrence 1Rectal Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hodgkin Disease 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × Pyridoxine × Clear all
NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡